AIM ImmunoTech Inc. (AIM)
AIM moved a median of -0.76% 30 minutes after news, and -1.37% by the close. How AIM actually reacts to news — the realized, point-in-time move the market made, measured across 415 labeled events over the last three years with zero look-ahead.
AIM’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.02% | 35% | 394 |
| 30-min | -0.76% | 35% | 403 |
| 60-min | -0.90% | 36% | 405 |
| to close | -1.37% | 36% | 402 |
| Middle 50% of AIM reactions | -3.07% to +1.07% |
|---|---|
| Median reaction (30-min) | -0.76% |
| Measured reactions | 415 |
Half of all AIM ImmunoTech Inc. news events land between -3.07% and +1.07% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when AIM moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AIM's baseline. Nothing else.
Recent AIM events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays | Press release | GlobeNewswire | +0.55% | +0.44% | |
| AIM ImmunoTech Highlights Recent Media Coverage of Ampligen’s® Broad-Spectrum Antiviral and Biodefense Potential | Press release | GlobeNewswire | -5.01% | +0.26% | |
| AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data | Press release | GlobeNewswire | -1.01% | +5.15% | |
| AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video | Press release | GlobeNewswire | -2.31% | -1.24% | |
| Form ARS AIM ImmunoTech Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.01% | +5.15% | |
| Form DEF 14A AIM ImmunoTech Inc. For: Sep 30 | SEC filing · Form DEF | SEC EDGAR | -1.01% | +5.15% | |
| Form 8-K AIM ImmunoTech Inc. For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | -3.16% | -5.07% | |
| Form 8-K AIM ImmunoTech Inc. For: Sep 03 | SEC filing · Form 8-K | SEC EDGAR | -2.78% | +0.18% | |
| AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video | Press release | GlobeNewswire | -0.04% | +1.83% | |
| Form 8-K AIM ImmunoTech Inc. For: Aug 31 | SEC filing · Form 8-K | SEC EDGAR | -1.54% | -1.67% | |
| AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041 | Press release | GlobeNewswire | +2.17% | +2.00% | |
| AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039 | Press release | GlobeNewswire | -6.60% | -36.84% | |
| AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference | Press release | GlobeNewswire | -0.20% | -0.79% | |
| AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article | Press release | GlobeNewswire | -0.87% | +1.14% | |
| Form 8-K AIM ImmunoTech Inc. For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | +0.39% | -2.04% | |
| AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer | Press release | GlobeNewswire | +1.78% | — | |
| Form 8-K AIM ImmunoTech Inc. For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | +1.78% | — | |
| Form 10-Q AIM ImmunoTech Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.78% | — | |
| Form 8-K AIM ImmunoTech Inc. For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | +0.19% | +8.11% | |
| Form 8-K AIM ImmunoTech Inc. For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | -1.10% | +7.87% | |
| AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point | Press release | GlobeNewswire | -2.97% | -1.97% | |
| Form 8-K AIM ImmunoTech Inc. For: Jul 15 | SEC filing · Form 8-K | SEC EDGAR | +0.21% | -3.56% | |
| Form S-8 AIM ImmunoTech Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.00% | -2.85% | |
| AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program | Press release | GlobeNewswire | -3.17% | +1.83% | |
| Form DEF 14A AIM ImmunoTech Inc. For: Jun 25 | SEC filing · Form DEF | SEC EDGAR | +1.83% | -2.01% | |
| AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones | Press release | GlobeNewswire | -3.69% | +5.44% | |
| Form EFFECT AIM ImmunoTech Inc. | SEC filing · Form EFFECT | SEC EDGAR | -3.69% | +5.44% | |
| AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series | Press release | GlobeNewswire | -1.42% | +0.76% | |
| AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer | Press release | GlobeNewswire | -2.61% | -3.90% | |
| Form S-1 AIM ImmunoTech Inc. | SEC filing · Form S-1 | SEC EDGAR | -2.61% | -3.90% | |
| Form EFFECT AIM ImmunoTech Inc. | SEC filing · Form EFFECT | SEC EDGAR | -0.05% | +3.31% | |
| AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency | Press release | GlobeNewswire | -1.91% | -10.74% | |
| Form 8-K AIM ImmunoTech Inc. For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | -1.91% | -10.74% | |
| Form PRE 14A AIM ImmunoTech Inc. For: Jun 15 | SEC filing · Form PRE | SEC EDGAR | +1.73% | +6.37% | |
| Form 8-K AIM ImmunoTech Inc. For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | +1.60% | -2.80% | |
| Form 8-K AIM ImmunoTech Inc. For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | -1.66% | +6.04% | |
| AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules | Press release | GlobeNewswire | -9.33% | -16.04% | |
| AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer | Press release | GlobeNewswire | -3.07% | -15.83% | |
| Form S-1 AIM ImmunoTech Inc. | SEC filing · Form S-1 | SEC EDGAR | -9.33% | -16.04% | |
| AIM ImmunoTech Releases Virtual Investor ‘What This Means’ Video Segment Discussing Ampligen’s Potential in Ebola Virus Disease Preparedness | Press release | GlobeNewswire | -13.18% | -24.19% | |
| Form 8-K AIM ImmunoTech Inc. For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | -13.18% | -24.19% | |
| AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones | Press release | GlobeNewswire | -1.37% | +61.94% | |
| AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration | Press release | GlobeNewswire | -2.10% | +61.73% | |
| Form 8-K AIM ImmunoTech Inc. For: May 20 | SEC filing · Form 8-K | SEC EDGAR | -0.52% | -2.60% | |
| AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement | Press release | GlobeNewswire | — | -41.80% | |
| AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities | Press release | GlobeNewswire | -4.58% | +12.11% | |
| Form 8-K AIM ImmunoTech Inc. For: May 18 | SEC filing · Form 8-K | SEC EDGAR | -4.58% | +12.11% | |
| Form 10-Q AIM ImmunoTech Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +4.50% | +48.04% | |
| AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer | Press release | GlobeNewswire | +1.79% | -5.98% | |
| Form 8-K AIM ImmunoTech Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +1.79% | -5.98% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AIM section they belong to.
Where else AIM is measured.
AIM earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is AIM ImmunoTech Inc.'s median reaction calculated?
Every labeled AIM news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 415 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 35% of AIM's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does AIM's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.